Israel Institute for Biological Research COVID-19 Vaccine Candidate Moving to Phase 1 Clinical Trials

Israel Institute for Biological Research COVID-19 Vaccine Candidate Moving to Phase 1 Clinical Trials

Israel’s Institute for Biological Research (IIRB) has developed a COVID-19 vaccine candidate based on another virus, purportedly so it isn’t harmful to humans. Now the Israeli sponsor will conduct human clinical trials involving 100 volunteers at Sheba and Hadassah Medical centers starting in October. This news followed information that the early stage vaccine showed promise after preclinical research in animals. Perhaps this vaccine could be part of a second wave or version 2.0 of vaccines later in 2021?

Hadassah Medical Center Ready

According to Jerusalem Post, Zeev Rotstein, Director-General of Hadassah Medical Center, reports to Ynet that the study team at the prestigious Israeli medical center is ready to conduct a vaccine trial. China’s Xinhuanet also reported on this news.

20% of Israelis Say No to Vaccine

In a recent survey, up to 20% of Israelis would not take a vaccine. TrialSite recently suggested that this first wave of vaccine can be considered “Version 1.0” and that many people may be hesitant to be first, rather opting to wait until researchers learn more about these experimental vaccines, even if proven. The amount of distrust in government and big pharmaceutical companies is palpable, and TrialSite observes many of the concerns via direct viewer emails and comments.

Trust is Key

Developing and nurturing of trust between health systems, government agencies, vaccine sponsors directly with consumers is absolutely key. One premise behind TrialSite and its unbiased, apolitical point of view is exactly that—a mission to pursue the truth, regardless of position, financial gain or other matters that can interrupt the development of trust with people. Perhaps the winning brands of the future will be those that embrace a more open, accessible and humble approach?